酒精性肝病不是代谢相关性脂肪性肝病

doi:10.3969/j.issn.1672-5069.2025.01.002

Abstract

Su Ya, Wang Bingyuan. Alcoholic liver disease is not metabolic associated fatty liver disease[J]. Journal of Practical Hepatology, 2025, 28(1): 5-8.

[1] Devarbhavi H,Asrani SK,Arab JP,et al.Global burden of liver disease:2023 update.J Hepatol,2023,79(2):516-537.
[2] Eslam M,Sanyal AJ,George J.Toward more accurate nomenclature for fatty liver diseases.Gastroenterology,2019,157(3):590-593.
[3] Eslam M,Newsome PN,Sarin SK,et al.A new definition for metabolic dysfunction-associated fatty liver disease:An international expert consensus statement.J Hepatol,2020,73(1):202-209.
[4] Fan J,Luo S,Ye Y,et al.Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population.Nutr Metab(Lond),2021,18(1):82.
[5] Tsutsumi T,Eslam M,Kawaguchi T,et al.MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD:Generalized estimating equation approach.Hepatol Res,2021,51(11):1115-1128.
[6] Eslam M,Sanyal AJ,George J.International consensus panel.MAFLD:a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology,2020,158(7):1999-2014.
[7] Kawaguchi T,Tsutsumi T,Nakano D,et al.MAFLD enhances clinical practice for liver disease in the Asia-Pacific region.Clin Mol Hepatol,2022,28(2):150-163.
[8] Valenti L,Pelusi S.Redefining fatty liver disease classification in 2020.Liver Int,2020,40(5):1016-1017.
[9] Eslam M,Newsome PN,Sarin SK,et al.A new definition for metabolic dysfunction-associated fatty liver disease:an international expert consensus statement.J Hepatol,2020,73(1):202-209.
[10] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.酒精性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2):170-176.
[11] Singal AK,Bataller R,Ahn J,et al.ACG clinical guideline:alcoholic liver disease.Am J Gastroenterol,2018,113(2):175-194.
[12] European Association for the Study of the Liver.Electronic address:easl-office@easloffice.eu;European association for the study of the liver. eassl clinical practice guidelines:management of alcohol-related liver disease.J Hepatol,2018,69(1):154-181.
[13] Fan JG,Cai XB,Li L,et al.Alcohol consumption and metabolic syndrome among Shanghai adults:a randomized multistage stratified cluster sampling investigation.World J Gastroenterol,2008,14(15):2418-2424.
[14] Heredia NI,Dong Q,Chang S,et al.Association of alcohol use and physical activity with body mass index in mexican-origin adults.J Racial Ethn Health Disparities,2022,9(3):812-819.
[15] 张鸿,袁乐媛,王炳元.酒精性肝病与代谢综合征.胃肠病学和肝病学杂志,2013,22(8):826-829.
[16] Lee CH,Lui DT,Lam KS.Non-alcoholic fatty liver disease and type 2 diabetes:an update.J Diabetes Investig,2022,13(6):930-940.
[17] Sebastian BM,Roychowdhury S,Tang H,et al.Identification of a cytochrome P4502E1/Bid/C1q-dependent axis mediating inflammation in adipose tissue after chronic ethanol feeding to mice.J Biol Chem,2011,286(41):35989-35997.
[18] Hwang S,Gao B.How does your fat affect your liver when you drink? J Clin Invest,2019,129(6):2181-2183.
[19] Mathur M,Yeh YT,Arya RK,et al.Adipose lipolysis is important for ethanol to induce fatty liver in the National Institute on Alcohol Abuse and Alcoholism murine model of chronic and binge ethanol feeding.Hepatology, 2023,77(5):1688-1701.
[20] Wei X,Shi X,Zhong W,et al.Chronic alcohol exposure disturbs lipid homeostasis at the adipose tissue-liver axis in mice:analysis of triacylglycerols using high-resolution mass spectrometry in combination with in vivo metabolite deuterium labeling.PLoS One,2013,8(2):e55382.
[21] Vacca A,Bulfone L,Cicco S,et al.Alcohol intake and arterial hypertension: retelling of a multifaceted story.Nutrients,2023,15(4):958.
[22] Marchi KC,Muniz JJ,Tirapelli CR.Hypertension and chronic ethanol consumption: What do we know after a century of study? World JCardiol,2014,6(5):283-294.
[23] Fuchs FD,Fuchs SC.The effect of alcohol on blood pressure and hypertension.Curr Hypertens Rep,2021,23(10):42.
[24] Lechner K,McKenzie AL,Kränkel N, et al.High-risk atherosclerosis and metabolic phenotype:the roles of ectopic adiposity,atherogenic dyslipidemia,and inflammation.Metab Syndr Relat Disord,2020,18(4):176-185.
[25] Kasper P,Martin A,Lang S,et al.NAFLD and cardiovascular diseases:a clinical review.Clin Res Cardiol,2021,110(7):921-937.
[26] Puddey IB,Zilkens RR,Croft KD,et al.Alcohol and endothelial function:a brief review.Clin Exp Pharmacol Physiol,2001,28(12):1020-1024.
[27] 袁乐媛,王炳元.脂肪肝患者饮酒量与代谢因素相关性分析.胃肠病学和肝病学杂志,2015,24(4):441-443.
[28] Rocco A,Compare D,Angrisani D,et al.Alcoholic disease:liver and beyond. World J Gastroenterol,2014,20(40):14652-14659.
[29] Braet C,Hussein Agha Y,Taleb A,et al.Sulfonylurea-induced hypoglycemia in a patient with cirrhosis.Cureus,2020,12(6):e8513.
[30] Rosales C,Gillard BK,Gotto AM Jr,et al.The alcohol-high-density lipoprotein athero-protective axis.Biomolecules,2020,10(7):987.
[31] Van Tol A,Groener JE,Scheek LM,et al.Induction of net mass lipid transfer reactions in plasma by wine consumption with dinner.Eur J Clin Invest,1995,25(6):390-395.
[32] Beulens JW,Rimm EB,Ascherio A,et al.Alcohol consumption and risk for coronary heart disease among men with hypertension.Ann Intern Med,2007,146(1):10-19.
[33] De Oliveira E Silva ER,Foster D,McGee Harper M,et al.Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II.Circulation,2000,102(19):2347-2352.
[34] Åberg F,Byrne CD,Pirola CJ,et al.Alcohol consumption and metabolic syndrome:clinical and epidemiological impact on liver disease.J Hepatol, 2023,78(1):191-206.
[35] Hagström H,Thiele M,Roelstraete B,et al.Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients.Gut,2021,70(1):170-179.

Alcoholic liver disease is not metabolic associated fatty liver disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Sun Furong, Wang Bingyuan. Management of patients with alcohol consumption disorder [J]. Journal of Practical Hepatology, 2025, 28(1): 1-4.
[2]	Zhao Caixia, Yang Song. Fecal microbiota transplantation in treatment of patients with severe alcoholic hepatitis [J]. Journal of Practical Hepatology, 2025, 28(1): 9-12.
[3]	Huang Jiawei, Ji Yali, Zhou Ling, et al. SAF score and fatty liver inhibition of progression algorithm in evaluation of liver fibrosis in patients with metabolic associated fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(1): 48-51.
[4]	Ma Min, Xu Qiaoyun. Clinical implications of serum arginase-1 levels and apolipoprotein B /apolipoprotein A1 ratio in patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(1): 52-55.
[5]	Shen Yue, Zhu Ning, Wang Hai. Diagnostic performance of FibroTouch parameters in the diagnosis of non-alcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2025, 28(1): 60-63.
[6]	Jia Jihui, Zhang Yizhi, Lin Jing, et al. Down-regulation of hepatic SREBP1 and PPAR-γ expression by naringin in mice with high-fat diet-induced NAFLD [J]. Journal of Practical Hepatology, 2024, 27(6): 816-819.
[7]	Jia Shuangzhen, Wu Tianwei, Wu Jie. MicroRNA-122 in non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2024, 27(5): 646-649.
[8]	Li Yanmin, Zhang Wei, Hu Yanyan, et al. Clinical implication of serum TyG, visceral/subcutaneous fat area ratio and cardiac metabolic index in elderly patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2024, 27(5): 697-700.
[9]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease(Version 2024) [J]. Journal of Practical Hepatology, 2024, 27(4): 494-510.
[10]	Li Kaiyang, Zhao Qi, Huang Jing, et al. Non-alcoholic fatty liver diseases: Clinical trials registered in Chinese clinical trial registry [J]. Journal of Practical Hepatology, 2024, 27(4): 531-534.
[11]	Nong Xiaoli, Chen Fei, Zhan Haohong, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in individuals for physical examination [J]. Journal of Practical Hepatology, 2024, 27(3): 353-356.
[12]	Sun Shilei, Liu Cuicui, Li Shuguang, et al. Changes of serum fibroblast growth factor-21 and secreted frizzled related protein 5 in patients with non-alcoholic fatty liver disease and T2DM [J]. Journal of Practical Hepatology, 2024, 27(3): 357-360.
[13]	Gao Yang, Zhang Jing, Lu Xuanlin. Changes of serum IL-1RA, CTRP13 and CK-18 levels in patients with non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2024, 27(2): 185-188.
[14]	Li Min, Zhang Li, Zeng Ai, et al.. Liver fibrosis in patients with diabetes mellitus type 2 and non-alcoholic fatty liver diseases [J]. Journal of Practical Hepatology, 2024, 27(2): 193-197.
[15]	Zheng Bo, Halida.Xiaerfuhazi, Tan Li. Changes of serum HIF-1α, HMGB1 and adiponectin levels in patients with non-alcoholic fatty liver diseases and their correlation to carotid atherosclerosis [J]. Journal of Practical Hepatology, 2024, 27(2): 198-201.